Dec. 5, 2019—Veracyte and NanoString have entered into an agreement in which Veracyte has obtained exclusive global rights to develop and commercialize diagnostic tests on NanoString’s nCounter Flex system.
Veracyte plans to expand the portfolio of nCounter-based diagnostic products with its Envisia classifier, for use in idiopathic pulmonary fibrosis diagnosis, to international customers in 2021 and expects its in-development nasal swab classifier, for use in lung cancer diagnosis, to follow in 2022. Veracyte has also acquired the rights to the NanoString 510(k)-cleared Prosigna Breast Cancer Assay and nCounter Dx LymphMark assay, which is currently available for research and investigational use only.
“We are excited to utilize NanoString’s world-class nCounter Flex platform to make our advanced genomic tests available to physicians and their patients globally, beginning with our pulmonology products,” Bonnie H. Anderson, chairman and CEO of Veracyte, said in a NanoString press release. “The robust performance and ease of use of the nCounter platform make it ideally suited to expand our market opportunity beyond our CLIA-certified laboratory in the United States.”
Veracyte will pay NanoString $50 million in cash and Veracyte stock plus up to $10 million in cash upon the commercial launch of Veracyte diagnostic tests for use on the nCounter platform.